Ann: Kazia joins GBM Agile, page-2

There is more but thought this extract worthy due to the last sentence.

Sydney, 11 December 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an
Australian oncology-focused biotechnology company, is pleased to announce that it’s lead
program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led,
multi-drug adaptive phase II / III study in glioblastoma. It is expected that data from GBM
AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory
agencies.